Spondyloarthritis & psoriatic arthritis
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and C-reactive protein (CRP) status
Authors' conclusion
In patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI-/CRP+ and MRI+/CRP- subgroups.
Study context
- Population
- Patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with active sacroiliitis on MRI and/or elevated CRP, treated with certolizumab pegol (CZP)
- Comparison
- Certolizumab pegol in nr-axSpA subgroups by baseline MRI and CRP status: MRI+/CRP+ vs MRI-/CRP+ vs MRI+/CRP-
Methodological detailsphase 3, multicentre, subgroup analysis by baseline MRI and CRP status, safety follow-up extension to Week 156
- Phase 3
- Multicentre
- Subgroup analysis by baseline MRI and CRP status
- Safety follow-up extension to Week 156
Primary result
As reported in the abstract
ASDAS-MI in CZP-randomised patients · Week 156
Further findings
- ASAS40 in CZP-randomised patients · Week 156 · observed case — MRI+/CRP-
- 65.2%
- ASAS40 in CZP-randomised patients: MRI+/CRP+ 76.9%
- ASAS40 in CZP-randomised patients: MRI-/CRP+ 62.5%
Original publication
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status. RMD Open. Published 9 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →